Poor prognosis of ovarian cancer with large cell neuroendocrine carcinoma: Case report and review of published works

Large cell neuroendocrine carcinoma (LCNEC) is well‐reported to result in unfavorable prognoses in many organ cancers while being rarely reported in gynecologic cancer, especially ovarian and endometrial cancers. Here we report a case of ovarian cancer with LCNEC which spread to distant organs withi...

Full description

Saved in:
Bibliographic Details
Published inThe journal of obstetrics and gynaecology research Vol. 40; no. 3; pp. 869 - 872
Main Authors Asada, Kayo, Kawana, Kei, Teshima, Shinichi, Saito, Ako, Kawabata, Masakiyo, Fujii, Tomoyuki
Format Journal Article
LanguageEnglish
Published Australia 01.03.2014
Subjects
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Large Cell - diagnosis
Carcinoma, Large Cell - pathology
Carcinoma, Large Cell - secondary
Carcinoma, Large Cell - therapy
Carcinoma, Neuroendocrine - diagnosis
Carcinoma, Neuroendocrine - drug therapy
Carcinoma, Neuroendocrine - pathology
Carcinoma, Neuroendocrine - surgery
Chemotherapy, Adjuvant
chromogranin A
Drug Resistance, Neoplasm
Fatal Outcome
Female
gynecologic cancer
Humans
Kaplan-Meier Estimate
large cell neuroendocrine carcinoma
Middle Aged
Neoplasm Staging
ovarian cancer
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - pathology
Ovarian Neoplasms - secondary
Ovarian Neoplasms - therapy
platinum‐based chemotherapy
Prognosis
Online AccessGet full text

Cover

More Information
Summary:Large cell neuroendocrine carcinoma (LCNEC) is well‐reported to result in unfavorable prognoses in many organ cancers while being rarely reported in gynecologic cancer, especially ovarian and endometrial cancers. Here we report a case of ovarian cancer with LCNEC which spread to distant organs within 1 year of primary surgery despite the fact that the post‐surgical stage was Ia. The case received platinum‐based chemotherapy as an adjuvant therapy after her curative surgery. However, LCNEC in the case was resistant to the chemotherapy. In our review of published works, ovarian cancer cases with LCNEC show poor prognoses regardless of adjuvant chemotherapy following complete resection. Median overall survival was 10 months in stage I cases. Development of chemotherapy sensitive for LCNEC is needed.
Bibliography:ObjectType-Case Study-3
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Review-1
ObjectType-Feature-5
ObjectType-Report-2
ObjectType-Article-4
ISSN:1341-8076
1447-0756
DOI:10.1111/jog.12235